🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT07119541
Active, not recruiting Not applicable

Testing an Alliance-Focused Dialectical Behaviour Therapy Training for Borderline Personality Disorder

NCT07119541 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2025-08-01
Last updated
2026-07-29

Condition(s) studied

Borderline Personality DisorderEmotion Dysregulation

Investigational drug(s) / intervention(s)

Alliance-Focused Dialectical Behavior Therapy plus Deliberate PracticeAlliance-Focused Dialectical Behavior Therapy plus Reflective Practice

Alliance-Focused Dialectical Behavior Therapy plus Deliberate Practice: The alliance-focused DBT training plus deliberate practice is a 4-session weekly intervention delivered to therapists working with individuals with borderline personality disorder or emotion dysregulation. This training intervention involves a didactic component, video analysis, and case-based learning. Deliberate practice methods (e.g., setting individualized training goals, skills coaching, feedback, and opportunities for repeated practice) will be integrated both within and between training sessions.

Alliance-Focused Dialectical Behavior Therapy plus Reflective Practice: The alliance-focused DBT training plus reflective practice is a 4-session weekly intervention delivered to therapists working with individuals with borderline personality disorder or emotion dysregulation. Trainings will involve a didactic component, video analysis, and case-based learning. Reflective practice methods (i.e., thinking about past experiences to gain insight for future actions) will be integrated both within and between training sessions.

Study summary

The study evaluates the feasibility, acceptability, and effect sizes of two alliance-focused dialectical behavior therapy (DBT) training interventions to improve therapists' abilities to recognize and respond to alliance ruptures with clients with borderline personality disorder (BPD). Participants will be randomly assigned to receive either a 4-week training as usual (TAU), which include didactic training plus reflective practice (i.e., thinking about past actions to gain insight for future actions) or a 4-week didactic training plus deliberate practice training (i.e., setting individualized training goals, skills coaching, and opportunities for repeated practice with expert feedback). A pre-post design will be used to assess effect sizes for change in participants' abilities to recognize and respond to alliance ruptures. Therapist characteristics will be assessed to determine moderating effects on training outcome. Feasibility and acceptability of the training intervention will be assessed following the trainings.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Participants must be over the age of 18 2. Participants must be regulated health professionals in Canada who are authorized to deliver psychotherapy as part of their scope of practice, or a students in training under the supervision of a regulated health professional in Canada authorized to deliver psychotherapy as part of their scope of practice. 3. Participants must currently be providing psychotherapy 4. Participants must have access to reliable internet service 5. Participants must indicate that they are available to attend the training intervention times provided 6. Participants must agree to participate in the 4 weekly training intervention 7. Participants must state willingness to comply with study procedures (i.e., to complete pre- and post-intervention research evaluations, and between training homework exercises. Exclusion Criteria: * None

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
York University Toronto Ontario

More York University trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07119541 on ClinicalTrials.gov ↗ ← All trials in Canada